Glucagon-like peptide-1 receptor agonists tied to higher thyroid cancer risk in first year of treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
pulmonologyadvisor1d
GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss
For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...
Endocrinology Advisor1d
GLP-1 Receptor Agonists May Have Broader Range of Benefits, Risks
With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...
Endocrinology Advisor3d
Select GLP-1 Receptor Agonists Reduce Risk of CKD Progression, ESKD, and MACE
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...
EurekAlert!1d
Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among us adults with overweight or obesity
In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within 1 year, but those without type 2 diabetes had higher ...
HealthDay on MSN5d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in ...
Renal & Urology News5d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
Authors say large, multisite study should provide reassurance for short-term risk. (HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased ...
Medscape2d
Drug-Drug Interactions With Glucagon-like Peptide-1 Receptor Agonists
Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...
gastroenterologyadvisor5d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
Glucagon-like peptide 1 receptor agonist use was not associated with an increased risk for thyroid cancer compared with use of dipeptidyl peptidase-4 inhibitors. HealthDay News — Glucagon-like peptide ...
emjreviews.com4d
GLP-1 Receptor Agonists Linked to Behavioural Side Effects
A RECENT population-based analysis has highlighted potential behavioural side effects associated with Glucagon-like peptide 1 ...
BMJ2d
GLP-1 agonists may raise risk of pulmonary aspiration during surgery, MHRA warns
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...